81282-60-2

Basic information

• Product Name: 2(3H)-Benzoxazolone,7-amino-(9CI)
• Synonyms: 7-Amino-2,3-dihydro-2-oxo-1,3-benzoxazole;7-amino-3h-1,3-benzoxazol-2-one;7-Amino-2-benzoxazolinone;2(3H)-Benzoxazolone,7-amino-(9CI);7-Amino-1,3-benzoxazol-2(3H)-one;7-Amino-2-benzoxazolone;7-Aminobenzo[d]oxazol-2(3H)-one
• CAS NO: 81282-60-2
• Molecular Formula: C₇H₆N₂O₂
• Molecular Weight: 150.13
• EINECS: 462-910-8
• Product Categories: AMINEPRIMARY;Chemical Amines;Amines;Aromatics;Heterocycles
• Mol File: 81282-60-2.mol

Chemical Properties

• Appearance: /
• Density: 1.438 g/cm³
• Refractive Index: 1.659
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 9.06±0.70(Predicted)
• CAS DataBase Reference: 2(3H)-Benzoxazolone,7-amino-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2(3H)-Benzoxazolone,7-amino-(9CI)(81282-60-2)
• EPA Substance Registry System: 2(3H)-Benzoxazolone,7-amino-(9CI)(81282-60-2)

Safety Data

• Hazardous Substances Data: 81282-60-2(Hazardous Substances Data)

Usage

Chemical Properties

Tan Solid

Uses

Intermediate for the preparation of bifeprunox mesylate

InChI:InChI=1/C7H6N2O2/c8-4-2-1-3-5-6(4)11-7(10)9-5/h1-3H,8H2,(H,9,10)

Upstream product

• 573-56-8 2,6-dinitrophenol 
• 603-87-2 2-amino-6-nitrophenol 
• 26386-88-9 diphenyl phosphoryl azide 
• 6358-08-3 4-chloro-6-nitro-2-aminophenol 
• 811810-67-0 5-chloro-7-nitrobenzo[d]oxazol-2(3H)-one 
• 81117-90-0 7-nitro-3H-benzooxazol-2-one 

Downstream Products

• 1338064-96-2 2-(4-(trifluoromethyl)phenyl)-N-(2,3-dihydro-2-oxobenzo[d]oxazol-7-yl)acetamide 
• 1338064-72-4 1-(4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-7-yl)urea 
• 1338064-73-5 1-(4-(trifluoromethyl)-2-(pyrrolidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-7-yl)urea 
• 1338064-74-6 1-(4-(trifluoromethyl)-2-(piperidin-1-yl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-7-yl)urea 
• 871367-14-5 7-bromo-1,3-benzoxazol-2(3H)-one 

Relevant articles and documents

MULTIPLE D2 A(NTA)GONISTS/H3 ANTAGONISTS FOR TREATMENT OF CNS-RELATED DISORDERS

The present invention relates to compounds compound according to Formula (III); and pharmaceutically acceptable salts, hydrates and solvates thereof. These compounds have D2receptor antagonist/(partial) agonist effects and H3antagonistic effects, pharmaceutical compositions thereof, and methods of using them for application in the prophylaxis or treatment of CNS disorders.

DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES

Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds are disclosed that are represented by general formula (I). Also disclosed, are pharmaceutical compositions including these compounds and methods of using these compounds and compositions for the

Synthesis of substituted benzoxazolinones by the curtius rearrangement: Crystal structures of Intermediates and by-products

3-Substituted salicyloyl chlorides were converted to salicyloyl azides (R = Br, NO2) which underwent thermal rearrangement and intramolecular cyclization to benzoxazolinones. The crystal structures of 7-substituted benz[d]oxazolin-2-ones (R = B

"TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION"

The invention discloses compounds of formula I wherein Y is a group of formula A, B, C, D, or E: and W, Q, n, R1, R2, R3, U1-U5, J and K have the meanings given in the description. The compounds of formula I are TRPV1 antagonists and are useful as active

TRPV1 vanilloid receptor antagonists with a bicyclic portion

The invention discloses compounds of formula I wherein Y s selected from a group of formula and W, Q, n, R1, R2, R3, U1-U5 have the meanings given in the description. The compounds of formula I are TRPV1 antagonists and are useful as active ingredients of pharmaceutical compositions for the treatment of pain and other conditions ameliorated by the inhibition of the vanilloid receptor TRPV1. 1.

POLYMORPHS OF PARDOPRUNOX

This invention relates to a process for the preparation of 7-(4-methyl-1-piperazinyl)benzoxazol-2(3H)-one hydrochloride, a partial dopamine-D2 receptor agonist and a full serotonin 5-HT1A receptor agonist. 7-(4-methyl-1-piperazinyl)benzoxazol-2(3H)-one hydrochloride The invention also relates to polymorphic forms of said compound, as well as to pharmaceutical compositions containing these compounds, to methods for preparing the compounds, to methods for preparing intermediates useful for their synthesis, and to methods for preparing compositions containing these compounds. The invention also relates to the use of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in conditions or diseases of the central nervous system, caused by disturbances of the dopaminergic and/or serotonergic systems, for example: anxiety disorders (including generalized anxiety, panic disorder and obsessive compulsive disorder), depression, autism, schizophrenia, Parkinson's disease, restless leg syndrome, and disturbances of cognition and memory.

3H-BENZOOXAZOL-2-ONE MODULATORS OF D2 RECEPTOR AND/OR 5-HT1A RECEPTOR

The present invention relates to new 3H-benzooxazol-2-one modulators of D2 receptors and/or 5-HT1A receptors, pharmaceutical compositions thereof, and methods of use thereof.

SPIROHYDANTOIN ARYL CGRP RECEPTOR ANTAGONISTS

Compounds of formula (I); (wherein variables A1, A2. A3, A4, A5, A6, A7, B3 E1, E2, E3, E4, E5, G1, G2 and R.6 are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

SPIROLACTAM ARYL CGRP RECEPTOR ANTAGONISTS

Compounds of formula (I): (wherein variables A1, A2, A3, A4, A5, A6, A7, E1, E2, E3, E4, E5, G1, G2, J and K are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same

The present disclosure provides novel pharmaceutical compounds and methods for making the same, novel pharmaceutical dosage forms and methods for making the same, and methods for using said compounds and dosage forms to treat and prevent diseases and/or d